Therapeutic insights into the treatment of triple-negative breast cancer: Protein kinase RNA activated-like ER kinase (PERK) inhibits triple-negative breast cancer progression via up regulation of its target gene, 9/April/2014, 10.44 am

Regulation of Telomerase gene expression and function: miR-133 regulates the expression of longevity gene telomerase via down regulation of its target gene, 9/April/2014, 8.34 am
April 9, 2014
Insights into the targeting of invasion and migration of breast cancer cells: Tumor suppressor p33(ING1b) suppresses the expression of oncoprotein HMGA1 via up regulation of its target gene, 9/April/2014, 14.30
April 9, 2014
Show all

Prof. Laurie H. Glimcher from Sandra and Edward Meyer Cancer Center of Weill Cornell Medical College, New York; Prof Matthew B. Greenblatt  from Department of Pathology, Brigham and Women’s Hospital, Harvard medical school, Boston, Massachusetts, USA; and others  have reported recently in the prestigious journal Nature (508, 103–107 (03 April 2014) that: “XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway

On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Therapeutic insights into the treatment of triple-negative breast cancer: Protein kinase RNA activated-like ER kinase (PERK) inhibits triple-negative  breast cancer progression via up regulation of its target gene.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathanTherapeutic insights into the treatment of triple-negative breast cancer: Protein kinase RNA activated-like ER kinase (PERK) inhibits triple-negative  breast cancer progression via up regulation of its target gene, 9/April/2014, 10.43 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Comments are closed.